3 completed, 2 enrolling by invitation, 2 recruiting, 1 unknown. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Enrolling by invitation 2, Recruiting 2, Completed 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow AADvac1: new trials by email Literature Review of AADvac1 trials Research Report on AADvac1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform AADvac1, LM11A-31 - Progressive Supranuclear Palsy(PSP) | Phase 2 | Recruiting | Adam Boxer | 440 | 2026-07-29 | 2026-11-10 |
| Alzheimer's Tau Platform: Master Protocol AADvac1, Tau2 - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Recruiting | Paul S. Aisen | 900 | 2026-07-06 | 2026-10-26 |
| A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia AADvac1 40 µg, AADvac1 160 µg - Primary Progressive Nonfluent Aphasia | Phase 1 | Unknown | Axon Neuroscience SE | 33 | 2017-07-31 | 2019-11-14 |
| 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease AADvac1, Placebo - Alzheimer's Disease | Phase 2 | Completed | Axon Neuroscience SE | 208 | 2016-03-01 | 2019-11-14 |
| 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease AADvac1 - Alzheimer's Disease | Phase 1 | Completed | Axon Neuroscience SE | 25 | 2014-01-01 | 2017-03-17 |
| Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease AADvac1, Placebo - Alzheimer Disease | Phase 1 | Completed | Axon Neuroscience SE | 30 | 2013-05-01 | 2015-10-12 |
Alzheimer Disease (5) · Pick Disease of the Brain (4) · Frontotemporal Dementia (3) · Dementia (2) · Supranuclear Palsy, Progressive (2) · Aphasia, Primary Progressive (1) · Cognitive Dysfunction (1) · Motor Activity (1) · Nerve Degeneration (1) · Primary Progressive Nonfluent Aphasia (1) · Tauopathies (1)
Axon Neuroscience SE (4) · Adam Boxer (2) · Paul S. Aisen (2)
United States (4) · Austria (3) · Germany (2) · Czechia (1) · Poland (1) · Romania (1) · Slovakia (1) · Slovenia (1) · Sweden (1)
Adam Boxer, MD, PhD (4) · Anne-Marie Wills, MD (2) · Irene Litvan, MD (2) · Julio Rojas-Martinez, MD, PhD (2) · Keith Johnson, MD (2) · Reinhold Schmidt, Professor (2) · Markus Otto, Prof (1) · Reinhold Schmidt, Prof. MD. (1)
PMID 27955995, PMID 30355322, PMID 25478017, PMID 39580468
R01AG078457 (2), R01AG085029 (2), 2015 (1), 2017 (1)